Table 2 Dose volume objectives, deviations, and benchmark case results (data for 36 cases)
From: Quality assurance of the SCOPE 1 trial in oesophageal radiotherapy
Structure &Â Dose Volume Objective | Minor Deviation | Major Deviation | Range Achieved | Number of Deviations |
|---|---|---|---|---|
Type a algorithm: PTV V95% > 99.0% | PTV deviations were not pre-classified but reviewed individually | 98.6–100.0% | 4 deviations (98.6, 98.8, 98.9, 98.9%) | |
Type a algorithm: PTV point minimum dose >93.0% | 86.5–96.5% | 2 deviations (86.5, 92.7%) | ||
Type b algorithm: PTV V95% > 99.0% - [0.4 x % PTVoverlap] | 92.4–99.3% | no deviations | ||
ICRU maximum dose <107% | 120% > max > 107% | max >120% | 103–108% | 2 minor deviations (108, 108%) |
Heart V40Gy < 30.0% | 50% > V40Gy > 30% | V40Gy > 50% | 16.1–33.0% | 1 minor deviation (33.0) |
Liver V30Gy < 60.0% | 70% > V30Gy > 60% | V30Gy > 70% | 0.0–4.2% | no deviations |
Combined lung V20Gy < 25.0% | 35% > V20Gy > 25% | V20Gy > 35% | 20.4–33.5% | 18 minor deviations (6 of which >30%) |
Spinal cord PRV D1cc < 40.0Gy | N/A | D1cc >40Gy | 34.2–41.5Gy | 2 major deviations (40.1, 41.5) |